ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial - ONTARGET

Description:

The goal of this trial was to determine whether the angiotensin-receptor blocker (ARB) telmisartan was noninferior to the angiotensin-converting enzyme (ACE) inhibitor ramipril, and whether a combination of the two drugs was superior to ramipril alone as a treatment to prevent vascular events in high-risk patients who had cardiovascular disease or diabetes mellitus, but did not have heart failure.